STOCK TITAN

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

NRx Pharmaceuticals (Nasdaq: NRXP) reported third-quarter results and began commercial sales following October 2026 FDA approval of preservative-free ketamine. Net patient service revenue rose to $1.2 million from $0.2 million a year earlier. Net loss narrowed to $2.2 million, or $0.05 per share, from $5.9 million, or $0.27 per share, while operating loss widened to $8.1 million from $4.0 million.

Selling began the week of November 9; the first order is received and shipments are scheduled by January 2027. Quarter-end cash was $19.8 million, with no convertible debt. NRx aims to submit a rolling NRX-100 drug application by year-end 2026, supported by a Yale collaboration. NRx Defense Systems received an $11.25 million DARPA contract for a Phase 3 trial. NRx also introduced subcutaneous ketamine candidate NRX-200, with initial human testing targeted for September 2027.

Loading...
Loading translation...
16 points · 3 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Major pointPreservative-free ketamine received FDA approval in October 2026, ahead of the November 10 goal date.
  • Major pointJune 2026 common-stock offering raised approximately $22.3 million in gross proceeds. 24% of market cap
  • Major pointNRx Defense Systems received an $11.25 million DARPA prime contract for Phase 3 SPARC-TMS. 12% of market cap
  • Moderate pointThird-quarter net patient service revenue increased to $1.2 million from $0.2 million in 2025.
  • Moderate pointThird-quarter net loss narrowed to $2.2 million, or $0.05 per share, versus $5.9 million, or $0.27.
  • Moderate pointCash increased to $19.8 million at September 30, 2026, from $7.8 million at December 31, 2025.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.NRx targets a rolling NRX-100 application by year-end 2026.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.NRx targets profitability in 2027, funding innovation through non-dilutive sources wherever possible.
8 minor points
  • Minor point. Forward-looking: it has not happened yet and may not happen.Ketamine selling began the week of November 9; first order received, shipments scheduled no later than January 2027.
  • Minor pointNine-month net loss narrowed to $20.1 million from $29.0 million, primarily reflecting accounting measurements and non-recurring charges.
  • Minor pointQuarter-end balance sheet had no convertible debt.
  • Minor pointDARPA approved the first two invoices for payment in the fourth quarter of 2026.
  • Minor pointYale collaboration signed for a five-year study NRx believes can support NRX-100 accelerated approval.
  • Minor point. Forward-looking: it has not happened yet and may not happen.NRX-200 testing is expected in early 2027, with first-in-human testing targeted for September 2027.
  • Minor point. Forward-looking: it has not happened yet and may not happen.NRx estimates packaging-related unit costs at approximately $0.75, versus approximately $3.25 with glass.
  • Minor point. Forward-looking: it has not happened yet and may not happen.NRx intends to add additional already approved sterile products in 2027.

Negative

  • Major pointJune 2026 financing issued common stock, diluting existing holders.
  • Moderate pointThird-quarter operating loss widened to $8.1 million from $4.0 million in 2025.
  • Minor pointNine-month operating loss widened to $19.4 million from $11.6 million in 2025.
  • Minor pointThird-quarter selling, general and administrative expenses rose to $6.6 million from $2.8 million.
  • Minor pointThird-quarter research and development expenses rose to $1.8 million from $1.4 million.

News Explained

June 2026 common-stock offering raised $22.3 million gross and increased shares; September 30 cash equaled 271.7 days of third-quarter operating cash use at that rate.

NRx reported June 2026 gross proceeds of $22.3 million from an underwritten public offering of common stock; cash and equivalents were $19.8 million at September 30, 2026, compared with $7.8 million at December 31, 2025.

An underwritten offering involves an investment bank buying securities from the issuer and reselling them; issuing additional shares increases the share count and reduces existing holders’ percentage ownership, absent offsetting changes.

At September 30, 2026, cash and equivalents equaled 271.7 days of the last reported quarterly operating cash use at the third-quarter rate; this is a backward-looking comparison, not a forecast.

Sources and calculations
  • Available liquidity against the last reported quarterly operating outflow, in days at that rate $19,822,000 / ($6,712,000 / 92) = 271.7 days

Key Figures

Net patient service revenue: $1.2 million vs. $0.2 million Loss from operations: $8.1 million vs. $4.0 million Net loss: $2.2 million, or $0.05 per share, vs. $5.9 million, or $0.27 per share +5 more
Net patient service revenue
$1.2 million vs. $0.2 million
Third quarter 2026 vs. third quarter 2025
Loss from operations
$8.1 million vs. $4.0 million
Third quarter 2026 vs. third quarter 2025
Net loss
$2.2 million, or $0.05 per share, vs. $5.9 million, or $0.27 per share
Third quarter 2026 vs. third quarter 2025
Nine-month net loss
$20.1 million vs. $29.0 million
Nine months ended September 30, 2026 vs. the same period in 2025
Cash and cash equivalents
$19.8 million
As of September 30, 2026
DARPA prime contract
$11.25 million
October 2026 award to lead the SPARC-TMS Phase 3 trial
Estimated U.S. initial market
Approximately $400M; 15% annual growth
Company estimate for preservative-free ketamine
Estimated cost of goods per unit
Approximately $0.75 with BFS packaging vs. approximately $3.25 for glass
Company estimate

Previous Earnings Reports

3 past events · Latest: May 18
Same Type 3 events
  1. May 18

    Q1 earnings

    24h Move
    -5.0%

    Net loss narrowed year over year; shares declined 5.03%.

  2. Nov 17

    Q3 earnings

    24h Move
    -15.3%

    Operating loss increased year over year; shares declined 15.26%.

  3. Aug 18

    Q2 earnings

    24h Move
    -4.5%

    Net loss widened year over year; shares declined 4.5%.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

abbreviated new drug application, gdufa, blow-fill-seal, accelerated approval pathway, +2 more
6 terms
abbreviated new drug application regulatory
"approved the Company’s Abbreviated New Drug Application (ANDA)"
An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.
gdufa regulatory
"ahead of the November 10, 2026 GDUFA goal date"
GDUFA is a U.S. regulatory program that charges fees to makers of generic drugs to fund and speed up the government review and inspection process for generic medicines and manufacturing sites. For investors, it matters because the program influences how fast generics reach the market, the cost burden on manufacturers, and the ability of companies to scale production—similar to paying for faster processing at a government office that can affect a business’s timing and margins.
blow-fill-seal technical
"first FDA approval of a blow-fill-seal (BFS) vial"
An automated manufacturing process that forms a plastic container, fills it with a sterile liquid or drug, and seals it in one continuous, enclosed operation, reducing exposure to contaminants. Think of it like inflating a balloon, filling it with liquid, and tying it off without ever opening it to the air. For investors, blow-fill-seal matters because it improves product safety and consistency, lowers labor and contamination risk, speeds production, and can reduce regulatory and supply-chain hurdles—factors that affect costs, margins, and the ability to bring products to market reliably.
accelerated approval pathway regulatory
"confirmatory evidence required under FDA’s Accelerated Approval pathway"
The accelerated approval pathway is a process that allows new medicines to be approved more quickly based on early evidence that they may be effective, rather than waiting for full proof. This can help patients access promising treatments faster, but it also means ongoing studies are needed to confirm the benefits. For investors, it highlights potential faster market entry and earlier revenue opportunities, along with some uncertainty about long-term outcomes.
rolling new drug application regulatory
"submit a rolling New Drug Application (NDA) for NRX-100"
A rolling new drug application is a regulatory filing process where a company submits portions of its full drug application to a medicines regulator as each section is completed, rather than waiting to file the entire package at once. Think of it like sending chapters of a book to an editor as they are finished so review can start sooner; for investors it signals a potential acceleration of the formal review timeline and closer interaction with regulators.
pharmacokinetic medical
"Pharmacokinetic testing is expected to begin in early 2027"
Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FDA approved the Company’s first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales force

New Yale University collaboration supports the Accelerated Approval pathway for NRX-100; new pipeline product NRX-200 announced for subcutaneous ketamine

Management to host conference call and webcast today, November 17, 2026, at 8:00 a.m. ET

WILMINGTON, Del., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx” or the “Company”), a commercial-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

The third quarter and the weeks since mark NRx’s transition from a development-stage company to a commercial one, led by FDA approval of the Company’s first drug, preservative-free ketamine.

Key recent and third quarter highlights include:

  • FDA approval of preservative-free ketamine: On October 2026, the U.S. Food and Drug Administration (FDA) approved the Company’s Abbreviated New Drug Application (ANDA) for preservative-free ketamine, ahead of the November 10, 2026 GDUFA goal date. This is NRx’s first drug approval and, to the Company’s knowledge, the first FDA approval of a blow-fill-seal (BFS) vial with a luer-lock connection as a drug/device combination.
  • Commercial launch: NRx began selling preservative-free ketamine the week of November 9 with a 17-person sales force calling on hospitals and group purchasing organizations. The Company has received its first order and product shipments are scheduled to begin no later than January 2027.
  • Sterile injectable product opportunity: The company expects the initial market for preservative free ketamine to be approximately $400M in the US, growing at 15% per year. The company intends to add additional already approved sterile products that could double this market opportunity in 2027.
  • NRX-100 and Yale collaboration: Signed a collaboration agreement with Yale University, with the written approval of the Patient-Centered Outcomes Research Institute (PCORI), for NRx to join as a sponsor of a newly launched five-year PCORI study comparing IV ketamine with intranasal S-ketamine. The Company believes this study can provide the confirmatory evidence required under FDA’s Accelerated Approval pathway. NRx aims to submit a rolling New Drug Application (NDA) for NRX-100 by the end of 2026.
  • New pipeline product, NRX-200: Announced NRX-200, a proprietary, neutral-pH formulation of ketamine based on an already FDA-approved cyclodextrin vehicle, designed for subcutaneous delivery by infusion pump. Pharmacokinetic testing is expected to begin in early 2027, with a first-in-human trial targeted for September 2027.
  • DARPA prime contract: In October 2026, the Defense Advanced Research Projects Agency (DARPA) awarded NRx Defense Systems an $11.25 million prime contract to lead SPARC-TMS (NCT07227103), a Phase 3 trial of NRX-101 with rapid, robotic Transcranial Magnetic Stimulation (TMS). DARPA has approved the first two invoices for payment in the fourth quarter of 2026.
  • HOPE Therapeutics: Operates six locations in Florida and is treating patients with robotic, neuronavigated TMS in partnership with Zeta Surgical.
  • GeNeuro: GeNeuro plans to initiate clinical trials in ALS and schizophrenia in the second half of 2027, with support from the US, French, and Swiss governments.
  • Balance sheet: Ended the quarter with $19.8 million in cash and cash equivalents and no convertible debt.

The approved product is packaged in a BFS vial with a luer-lock connection, developed with Nephron Pharmaceuticals, that allows medication to be drawn directly into a syringe without a needle, eliminating needle-related sharps waste. Based on its prior experience with glass vials, the Company estimates its cost of goods with BFS packaging at approximately $0.75 per unit, compared with approximately $3.25 per unit for glass. The Company estimates current U.S. demand for sterile injectable ketamine at approximately $400 million, growing at more than 15% per year.

“The third quarter and the weeks since have marked NRx’s transition from a development-stage company to a commercial one,” said Dr. Jonathan Javitt, Founder, Chairman and Chief Executive Officer of NRx. “FDA approval of preservative-free ketamine is our first drug approval and the first for our blow-fill-seal luer-lock platform, which we believe can deliver sterile injectable products made in the United States at a fraction of the cost of glass and at net margins that rival those of innovative products. Our 17-person veteran sales force is in the field and we have received our first order. Each of our divisions is advancing: we aim to submit a rolling NDA for NRX-100 by year-end, with our new Yale collaboration supporting the Accelerated Approval pathway; we are introducing NRX-200 for subcutaneous ketamine delivery; and our DARPA-funded SPARC-TMS program is moving forward. Our goal for 2027 is to build a commercially successful company that demonstrates profitability, while funding our innovation through non-dilutive sources wherever possible.”

Financial Results for the Quarter Ended September 30, 2026

For the third quarter of 2026, net patient service revenue was $1.2 million, compared with $0.2 million for the third quarter of 2025, reflecting growth at the Company’s HOPE Therapeutics clinics.

Loss from operations for the third quarter of 2026 was $8.1 million, compared with $4.0 million for the third quarter of 2025. Selling, general and administrative expenses were $6.6 million, compared with $2.8 million, primarily reflecting preparation for the commercial launch of preservative-free ketamine. Research and development expenses were $1.8 million, compared with $1.4 million.

Net loss for the third quarter of 2026 was $2.2 million, or $0.05 per share, compared with $5.9 million, or $0.27 per share, for the third quarter of 2025.

For the nine months ended September 30, 2026, net loss was $20.1 million, compared with $29.0 million for the same period in 2025. The change was primarily related to fair value accounting measurements and other non-recurring charges related to the conversion and restructuring of previously issued convertible notes in the 2025 period, partially offset by higher operating expenses in the current period. Loss from operations for the nine months was $19.4 million, compared with $11.6 million for the same period in 2025, driven by higher cost of patient services from increased revenue at HOPE clinics, higher research and development expense, and higher selling, general and administrative expense related to the commercial launch.

As of September 30, 2026, cash and cash equivalents were $19.8 million, compared with $7.8 million as of December 31, 2025. The increase primarily reflects the Company’s June 2026 underwritten public offering of common stock, with gross proceeds of approximately $22.3 million.

Conference Call Details

NRx will host a conference call and webcast today, Tuesday, November 17, 2026, at 8:00 a.m. ET to discuss these results and provide a corporate update. The live webcast and an archived replay will be available in the Events section of the Company’s investor relations website at ir.nrxpharma.com/events.

Domestic: 1-800-717-1738
International: +1-646-307-1865

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a commercial-stage biopharmaceutical company developing therapeutics based on its NMDA receptor platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company has been awarded an Abbreviated New Drug Approval (ANDA) for Preservative-Free Ketamine and is seeking New Drug Approval for a presentation of intravenous ketamine (NRX-100) with approved claims for treating depression and suicidality.

In October 2026 the Defense Advanced Research Projects Agency awarded an $11.25 million contract to NRx to conduct a phase 3 trial of its oral drug NRX-101, (D-cycloserine/lurasidone) combined with Robotic Neuronavigated Transcranial Magnetic Stimulation as a one-day treatment for patients with depression. NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:
Brian Korb
Managing Partner
astr partners
(917) 653-5122
brian.korb@astrpartners.com

Media Contact:
Victoria Verdeja
RXMD
(305) 904-1038
vverdeja@rxmedyn.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were NRx Pharmaceuticals' third-quarter 2026 financial results?

NRx reported $1.2 million in net patient service revenue and a net loss of $2.2 million, or $0.05 per share. In the third quarter of 2025, revenue was $0.2 million and net loss was $5.9 million, or $0.27 per share. Operating loss widened to $8.1 million from $4.0 million.

When will NRx Pharmaceuticals ship its approved preservative-free ketamine?

Product shipments are scheduled to begin no later than January 2027. NRx began selling the product the week of November 9 with a 17-person sales force calling on hospitals and group purchasing organizations, and has received its first order.

What will the Yale study compare for NRx Pharmaceuticals' NRX-100 program?

The newly launched five-year study compares intravenous ketamine with intranasal S-ketamine. NRx signed an agreement to join as a sponsor with written approval from the Patient-Centered Outcomes Research Institute. The company believes the study can provide the confirmatory evidence required under the FDA's Accelerated Approval pathway.

What is NRx Pharmaceuticals' DARPA-funded SPARC-TMS trial testing?

SPARC-TMS is a Phase 3 trial of NRX-101 with rapid, robotic transcranial magnetic stimulation, a brain-stimulation treatment. DARPA awarded NRx Defense Systems an $11.25 million prime contract in October 2026 and approved the first two invoices for payment in the fourth quarter of 2026.

Keep reading